Bamco Inc. NY Sells 8,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Bamco Inc. NY reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 16.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,000 shares of the biopharmaceutical company's stock after selling 8,000 shares during the quarter. Bamco Inc. NY's holdings in Ultragenyx Pharmaceutical were worth $1,683,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in RARE. Wilmington Savings Fund Society FSB purchased a new position in Ultragenyx Pharmaceutical in the third quarter worth $83,000. Nordea Investment Management AB grew its position in shares of Ultragenyx Pharmaceutical by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company's stock worth $1,658,000 after buying an additional 3,246 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after purchasing an additional 294 shares in the last quarter. KBC Group NV lifted its holdings in Ultragenyx Pharmaceutical by 2,275.8% in the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock worth $2,567,000 after buying an additional 58,442 shares during the period. Finally, R Squared Ltd purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth $103,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Down 2.3 %

NASDAQ RARE traded down $0.82 during trading on Friday, hitting $35.16. The stock had a trading volume of 1,136,694 shares, compared to its average volume of 824,723. The company has a market capitalization of $3.30 billion, a PE ratio of -5.55 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37. The firm has a 50 day moving average price of $36.89 and a 200 day moving average price of $42.55.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. During the same period last year, the company earned ($2.03) earnings per share. The business's revenue for the quarter was up 28.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Morgan Stanley increased their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research report on Friday. Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Wedbush restated a "neutral" rating and set a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $90.93.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares of the company's stock, valued at $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas Richard Kassberg sold 6,028 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares of the company's stock, valued at approximately $11,166,519.80. This represents a 2.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 125,405 shares of company stock worth $5,285,169 in the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.